These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31706840)

  • 1. Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.
    Lee SE; Duran-Martinez M; Khantsis S; Bianchi DW; Guedj F
    Trends Mol Med; 2020 Feb; 26(2):150-169. PubMed ID: 31706840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Curr Opin Neurobiol; 2012 Oct; 22(5):880-6. PubMed ID: 22658745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.
    Busciglio J; Capone G; O'Bryan J; Gardiner KJ
    Cytogenet Genome Res; 2013; 141(4):260-71. PubMed ID: 24008277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathways to cognitive deficits in Down syndrome.
    Sturgeon X; Le T; Ahmed MM; Gardiner KJ
    Prog Brain Res; 2012; 197():73-100. PubMed ID: 22541289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Perspectives for the Rescue of Cognitive Disability in Down Syndrome.
    Bartesaghi R; Haydar TF; Delabar JM; Dierssen M; Martínez-Cué C; Bianchi DW
    J Neurosci; 2015 Oct; 35(41):13843-52. PubMed ID: 26468184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
    Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D
    Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.
    Rueda N; Flórez J; Martínez-Cué C
    Neural Plast; 2012; 2012():584071. PubMed ID: 22685678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome.
    Aziz NM; Guedj F; Pennings JLA; Olmos-Serrano JL; Siegel A; Haydar TF; Bianchi DW
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29716957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of animal models in the study of human pathologies: a mouse model of Down syndrome].
    Morice E
    Biol Aujourdhui; 2010; 204(1):3-8. PubMed ID: 20950569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: pharmacological intervention for Down syndrome cognitive deficits: emerging drug targets.
    Montesinos ML
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):6-7. PubMed ID: 24152331
    [No Abstract]   [Full Text] [Related]  

  • 12. Mouse models of Down syndrome: gene content and consequences.
    Gupta M; Dhanasekaran AR; Gardiner KJ
    Mamm Genome; 2016 Dec; 27(11-12):538-555. PubMed ID: 27538963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosage of the Abcg1-U2af1 region modifies locomotor and cognitive deficits observed in the Tc1 mouse model of Down syndrome.
    Marechal D; Lopes Pereira P; Duchon A; Herault Y
    PLoS One; 2015; 10(2):e0115302. PubMed ID: 25706610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it possible to improve neurodevelopmental abnormalities in Down syndrome?
    Bartesaghi R; Guidi S; Ciani E
    Rev Neurosci; 2011; 22(4):419-55. PubMed ID: 21819263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy 21 and Down syndrome: a short review.
    Sommer C; Henrique-Silva F
    Braz J Biol; 2008 May; 68(2):447-52. PubMed ID: 18660978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.
    Rueda N; Flórez J; Dierssen M; Martínez-Cué C
    Prog Brain Res; 2020; 251():245-268. PubMed ID: 32057309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age exacerbates abnormal protein expression in a mouse model of Down syndrome.
    Ahmed MM; Block A; Tong S; Davisson MT; Gardiner KJ
    Neurobiol Aging; 2017 Sep; 57():120-132. PubMed ID: 28641136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models.
    Galdzicki Z; Siarey R; Pearce R; Stoll J; Rapoport SI
    Brain Res Brain Res Rev; 2001 Apr; 35(2):115-45. PubMed ID: 11336779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteins of human chromosome 21.
    Gardiner K; Costa AC
    Am J Med Genet C Semin Med Genet; 2006 Aug; 142C(3):196-205. PubMed ID: 17048356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular Mechanism Underlying Abnormal Differentiation of Neural Progenitor Cells in the Developing Down Syndrome Brain].
    Kurabayashi N; Sanada K
    Yakugaku Zasshi; 2017; 137(7):795-800. PubMed ID: 28674289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.